Global Cardiac Marker Market
Global Cardiac Marker Market

Cardiac Marker Comprehensive Study by Type (Cardiac Troponin, Creatinine Kinase, CK-MB, Myoglobin), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, Others), Testing (Laboratory Testing, Point Of Care Testing) Players and Region - Global Market Outlook to 2024

Cardiac Marker Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Jul 2019 Edition 243 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study
Cardiac markers are the biomarkers measured to evaluate heat function, which helps to early prediction or diagnosis of the disease. They are used in the diagnosis and risk stratification of patients with chest pain and suspected acute coronary syndrome (ACS). Cardiac markers are endogenous substances released in the circulation due to damage or death of cardiac myocytes when the heart is damaged or stressed. Thus cardiac marker test helps patient for early diagnosis of the heart disease.

The market study is being classified by Type (Cardiac Troponin, Creatinine Kinase, CK-MB and Myoglobin), by Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis and Others) and major geographies with country level break-up.

Roche Diagnostics (Switzerland), Abbott Laboratories (United States), Siemens AG (Germany), BG Medicine (Cambodia), Biomerieux (France), Critical Diagnostics (United States), LSI Medience Corporation (Japan), diaDexus (United States), Danaher Corporation (United States) and Response Biomedical Corporation (Canada) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Singulex Inc. (United States), Thermo Fisher Scientific (United States), Trinity Biotech (Ireland) and Lee BioSolutions Inc. (United States).

Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Cardiac Marker market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Cardiac Marker market by Type, Application and Region.

On the basis of geography, the market of Cardiac Marker has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Testing, the sub-segment i.e. Laboratory Testing will boost the Cardiac Marker market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Rising Prevalence of Cardiovascular Diseases
  • Accuracy in the Cardiac Marker Testing
  • Low Cost of the Test

Market Trend
  • Technological Advancements Using Cardiac Biomarkers Combinations

Restraints
  • Technical Problems Related To Sample Collection and Storage

Opportunities
  • Growing Research and Development Activities
  • Increasing Geriatric Population Worldwide

Challenges
  • Issues Related To Regulatory and Reimbursement Systems


Market Leaders and their expansionary development strategies
Recently, Abbott laboratories acquired Alere Inc. to become a leader in point of care testing and significantly advancing global diagnostics presence. Abbott will be able to provide new, flexible, cost-effective, high-quality products to help health systems meet growing demand in both in-patient and out-patient settings.



Key Target Audience
Cardiac Marker Test Providers, Emerging Companies, Research Institutes, Government Body & Associations and End-user

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Cardiac Troponin
  • Creatinine Kinase
  • CK-MB
  • Myoglobin
By Application
  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Others
By Testing
  • Laboratory Testing
  • Point Of Care Testing

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Cardiovascular Diseases
      • 3.2.2. Accuracy in the Cardiac Marker Testing
      • 3.2.3. Low Cost of the Test
    • 3.3. Market Challenges
      • 3.3.1. Issues Related To Regulatory and Reimbursement Systems
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements Using Cardiac Biomarkers Combinations
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cardiac Marker, by Type, Application, Testing and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Cardiac Marker (Value)
      • 5.2.1. Global Cardiac Marker by: Type (Value)
        • 5.2.1.1. Cardiac Troponin
        • 5.2.1.2. Creatinine Kinase
        • 5.2.1.3. CK-MB
        • 5.2.1.4. Myoglobin
      • 5.2.2. Global Cardiac Marker by: Application (Value)
        • 5.2.2.1. Myocardial Infarction
        • 5.2.2.2. Congestive Heart Failure
        • 5.2.2.3. Acute Coronary Syndrome
        • 5.2.2.4. Atherosclerosis
        • 5.2.2.5. Others
      • 5.2.3. Global Cardiac Marker by: Testing (Value)
        • 5.2.3.1. Laboratory Testing
        • 5.2.3.2. Point Of Care Testing
      • 5.2.4. Global Cardiac Marker Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Cardiac Marker: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche Diagnostics (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott Laboratories (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Siemens AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. BG Medicine (Cambodia)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Biomerieux (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Critical Diagnostics (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. LSI Medience Corporation (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. DiaDexus (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Danaher Corporation (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Response Biomedical Corporation (Canada)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cardiac Marker Sale, by Type, Application, Testing and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Cardiac Marker (Value)
      • 7.2.1. Global Cardiac Marker by: Type (Value)
        • 7.2.1.1. Cardiac Troponin
        • 7.2.1.2. Creatinine Kinase
        • 7.2.1.3. CK-MB
        • 7.2.1.4. Myoglobin
      • 7.2.2. Global Cardiac Marker by: Application (Value)
        • 7.2.2.1. Myocardial Infarction
        • 7.2.2.2. Congestive Heart Failure
        • 7.2.2.3. Acute Coronary Syndrome
        • 7.2.2.4. Atherosclerosis
        • 7.2.2.5. Others
      • 7.2.3. Global Cardiac Marker by: Testing (Value)
        • 7.2.3.1. Laboratory Testing
        • 7.2.3.2. Point Of Care Testing
      • 7.2.4. Global Cardiac Marker Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cardiac Marker: by Type(USD Million)
  • Table 2. Cardiac Marker Cardiac Troponin , by Region USD Million (2013-2018)
  • Table 3. Cardiac Marker Creatinine Kinase , by Region USD Million (2013-2018)
  • Table 4. Cardiac Marker CK-MB , by Region USD Million (2013-2018)
  • Table 5. Cardiac Marker Myoglobin , by Region USD Million (2013-2018)
  • Table 6. Cardiac Marker: by Application(USD Million)
  • Table 7. Cardiac Marker Myocardial Infarction , by Region USD Million (2013-2018)
  • Table 8. Cardiac Marker Congestive Heart Failure , by Region USD Million (2013-2018)
  • Table 9. Cardiac Marker Acute Coronary Syndrome , by Region USD Million (2013-2018)
  • Table 10. Cardiac Marker Atherosclerosis , by Region USD Million (2013-2018)
  • Table 11. Cardiac Marker Others , by Region USD Million (2013-2018)
  • Table 12. Cardiac Marker: by Testing(USD Million)
  • Table 13. Cardiac Marker Laboratory Testing , by Region USD Million (2013-2018)
  • Table 14. Cardiac Marker Point Of Care Testing , by Region USD Million (2013-2018)
  • Table 15. South America Cardiac Marker, by Country USD Million (2013-2018)
  • Table 16. South America Cardiac Marker, by Type USD Million (2013-2018)
  • Table 17. South America Cardiac Marker, by Application USD Million (2013-2018)
  • Table 18. South America Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 19. Brazil Cardiac Marker, by Type USD Million (2013-2018)
  • Table 20. Brazil Cardiac Marker, by Application USD Million (2013-2018)
  • Table 21. Brazil Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 22. Argentina Cardiac Marker, by Type USD Million (2013-2018)
  • Table 23. Argentina Cardiac Marker, by Application USD Million (2013-2018)
  • Table 24. Argentina Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 25. Rest of South America Cardiac Marker, by Type USD Million (2013-2018)
  • Table 26. Rest of South America Cardiac Marker, by Application USD Million (2013-2018)
  • Table 27. Rest of South America Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 28. Asia Pacific Cardiac Marker, by Country USD Million (2013-2018)
  • Table 29. Asia Pacific Cardiac Marker, by Type USD Million (2013-2018)
  • Table 30. Asia Pacific Cardiac Marker, by Application USD Million (2013-2018)
  • Table 31. Asia Pacific Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 32. China Cardiac Marker, by Type USD Million (2013-2018)
  • Table 33. China Cardiac Marker, by Application USD Million (2013-2018)
  • Table 34. China Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 35. Japan Cardiac Marker, by Type USD Million (2013-2018)
  • Table 36. Japan Cardiac Marker, by Application USD Million (2013-2018)
  • Table 37. Japan Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 38. India Cardiac Marker, by Type USD Million (2013-2018)
  • Table 39. India Cardiac Marker, by Application USD Million (2013-2018)
  • Table 40. India Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 41. South Korea Cardiac Marker, by Type USD Million (2013-2018)
  • Table 42. South Korea Cardiac Marker, by Application USD Million (2013-2018)
  • Table 43. South Korea Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 44. Taiwan Cardiac Marker, by Type USD Million (2013-2018)
  • Table 45. Taiwan Cardiac Marker, by Application USD Million (2013-2018)
  • Table 46. Taiwan Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 47. Australia Cardiac Marker, by Type USD Million (2013-2018)
  • Table 48. Australia Cardiac Marker, by Application USD Million (2013-2018)
  • Table 49. Australia Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 50. Rest of Asia-Pacific Cardiac Marker, by Type USD Million (2013-2018)
  • Table 51. Rest of Asia-Pacific Cardiac Marker, by Application USD Million (2013-2018)
  • Table 52. Rest of Asia-Pacific Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 53. Europe Cardiac Marker, by Country USD Million (2013-2018)
  • Table 54. Europe Cardiac Marker, by Type USD Million (2013-2018)
  • Table 55. Europe Cardiac Marker, by Application USD Million (2013-2018)
  • Table 56. Europe Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 57. Germany Cardiac Marker, by Type USD Million (2013-2018)
  • Table 58. Germany Cardiac Marker, by Application USD Million (2013-2018)
  • Table 59. Germany Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 60. France Cardiac Marker, by Type USD Million (2013-2018)
  • Table 61. France Cardiac Marker, by Application USD Million (2013-2018)
  • Table 62. France Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 63. Italy Cardiac Marker, by Type USD Million (2013-2018)
  • Table 64. Italy Cardiac Marker, by Application USD Million (2013-2018)
  • Table 65. Italy Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 66. United Kingdom Cardiac Marker, by Type USD Million (2013-2018)
  • Table 67. United Kingdom Cardiac Marker, by Application USD Million (2013-2018)
  • Table 68. United Kingdom Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 69. Netherlands Cardiac Marker, by Type USD Million (2013-2018)
  • Table 70. Netherlands Cardiac Marker, by Application USD Million (2013-2018)
  • Table 71. Netherlands Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 72. Rest of Europe Cardiac Marker, by Type USD Million (2013-2018)
  • Table 73. Rest of Europe Cardiac Marker, by Application USD Million (2013-2018)
  • Table 74. Rest of Europe Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 75. MEA Cardiac Marker, by Country USD Million (2013-2018)
  • Table 76. MEA Cardiac Marker, by Type USD Million (2013-2018)
  • Table 77. MEA Cardiac Marker, by Application USD Million (2013-2018)
  • Table 78. MEA Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 79. Middle East Cardiac Marker, by Type USD Million (2013-2018)
  • Table 80. Middle East Cardiac Marker, by Application USD Million (2013-2018)
  • Table 81. Middle East Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 82. Africa Cardiac Marker, by Type USD Million (2013-2018)
  • Table 83. Africa Cardiac Marker, by Application USD Million (2013-2018)
  • Table 84. Africa Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 85. North America Cardiac Marker, by Country USD Million (2013-2018)
  • Table 86. North America Cardiac Marker, by Type USD Million (2013-2018)
  • Table 87. North America Cardiac Marker, by Application USD Million (2013-2018)
  • Table 88. North America Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 89. United States Cardiac Marker, by Type USD Million (2013-2018)
  • Table 90. United States Cardiac Marker, by Application USD Million (2013-2018)
  • Table 91. United States Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 92. Canada Cardiac Marker, by Type USD Million (2013-2018)
  • Table 93. Canada Cardiac Marker, by Application USD Million (2013-2018)
  • Table 94. Canada Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 95. Mexico Cardiac Marker, by Type USD Million (2013-2018)
  • Table 96. Mexico Cardiac Marker, by Application USD Million (2013-2018)
  • Table 97. Mexico Cardiac Marker, by Testing USD Million (2013-2018)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Cardiac Marker: by Type(USD Million)
  • Table 109. Cardiac Marker Cardiac Troponin , by Region USD Million (2019-2024)
  • Table 110. Cardiac Marker Creatinine Kinase , by Region USD Million (2019-2024)
  • Table 111. Cardiac Marker CK-MB , by Region USD Million (2019-2024)
  • Table 112. Cardiac Marker Myoglobin , by Region USD Million (2019-2024)
  • Table 113. Cardiac Marker: by Application(USD Million)
  • Table 114. Cardiac Marker Myocardial Infarction , by Region USD Million (2019-2024)
  • Table 115. Cardiac Marker Congestive Heart Failure , by Region USD Million (2019-2024)
  • Table 116. Cardiac Marker Acute Coronary Syndrome , by Region USD Million (2019-2024)
  • Table 117. Cardiac Marker Atherosclerosis , by Region USD Million (2019-2024)
  • Table 118. Cardiac Marker Others , by Region USD Million (2019-2024)
  • Table 119. Cardiac Marker: by Testing(USD Million)
  • Table 120. Cardiac Marker Laboratory Testing , by Region USD Million (2019-2024)
  • Table 121. Cardiac Marker Point Of Care Testing , by Region USD Million (2019-2024)
  • Table 122. South America Cardiac Marker, by Country USD Million (2019-2024)
  • Table 123. South America Cardiac Marker, by Type USD Million (2019-2024)
  • Table 124. South America Cardiac Marker, by Application USD Million (2019-2024)
  • Table 125. South America Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 126. Brazil Cardiac Marker, by Type USD Million (2019-2024)
  • Table 127. Brazil Cardiac Marker, by Application USD Million (2019-2024)
  • Table 128. Brazil Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 129. Argentina Cardiac Marker, by Type USD Million (2019-2024)
  • Table 130. Argentina Cardiac Marker, by Application USD Million (2019-2024)
  • Table 131. Argentina Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 132. Rest of South America Cardiac Marker, by Type USD Million (2019-2024)
  • Table 133. Rest of South America Cardiac Marker, by Application USD Million (2019-2024)
  • Table 134. Rest of South America Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 135. Asia Pacific Cardiac Marker, by Country USD Million (2019-2024)
  • Table 136. Asia Pacific Cardiac Marker, by Type USD Million (2019-2024)
  • Table 137. Asia Pacific Cardiac Marker, by Application USD Million (2019-2024)
  • Table 138. Asia Pacific Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 139. China Cardiac Marker, by Type USD Million (2019-2024)
  • Table 140. China Cardiac Marker, by Application USD Million (2019-2024)
  • Table 141. China Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 142. Japan Cardiac Marker, by Type USD Million (2019-2024)
  • Table 143. Japan Cardiac Marker, by Application USD Million (2019-2024)
  • Table 144. Japan Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 145. India Cardiac Marker, by Type USD Million (2019-2024)
  • Table 146. India Cardiac Marker, by Application USD Million (2019-2024)
  • Table 147. India Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 148. South Korea Cardiac Marker, by Type USD Million (2019-2024)
  • Table 149. South Korea Cardiac Marker, by Application USD Million (2019-2024)
  • Table 150. South Korea Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 151. Taiwan Cardiac Marker, by Type USD Million (2019-2024)
  • Table 152. Taiwan Cardiac Marker, by Application USD Million (2019-2024)
  • Table 153. Taiwan Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 154. Australia Cardiac Marker, by Type USD Million (2019-2024)
  • Table 155. Australia Cardiac Marker, by Application USD Million (2019-2024)
  • Table 156. Australia Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 157. Rest of Asia-Pacific Cardiac Marker, by Type USD Million (2019-2024)
  • Table 158. Rest of Asia-Pacific Cardiac Marker, by Application USD Million (2019-2024)
  • Table 159. Rest of Asia-Pacific Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 160. Europe Cardiac Marker, by Country USD Million (2019-2024)
  • Table 161. Europe Cardiac Marker, by Type USD Million (2019-2024)
  • Table 162. Europe Cardiac Marker, by Application USD Million (2019-2024)
  • Table 163. Europe Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 164. Germany Cardiac Marker, by Type USD Million (2019-2024)
  • Table 165. Germany Cardiac Marker, by Application USD Million (2019-2024)
  • Table 166. Germany Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 167. France Cardiac Marker, by Type USD Million (2019-2024)
  • Table 168. France Cardiac Marker, by Application USD Million (2019-2024)
  • Table 169. France Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 170. Italy Cardiac Marker, by Type USD Million (2019-2024)
  • Table 171. Italy Cardiac Marker, by Application USD Million (2019-2024)
  • Table 172. Italy Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 173. United Kingdom Cardiac Marker, by Type USD Million (2019-2024)
  • Table 174. United Kingdom Cardiac Marker, by Application USD Million (2019-2024)
  • Table 175. United Kingdom Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 176. Netherlands Cardiac Marker, by Type USD Million (2019-2024)
  • Table 177. Netherlands Cardiac Marker, by Application USD Million (2019-2024)
  • Table 178. Netherlands Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 179. Rest of Europe Cardiac Marker, by Type USD Million (2019-2024)
  • Table 180. Rest of Europe Cardiac Marker, by Application USD Million (2019-2024)
  • Table 181. Rest of Europe Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 182. MEA Cardiac Marker, by Country USD Million (2019-2024)
  • Table 183. MEA Cardiac Marker, by Type USD Million (2019-2024)
  • Table 184. MEA Cardiac Marker, by Application USD Million (2019-2024)
  • Table 185. MEA Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 186. Middle East Cardiac Marker, by Type USD Million (2019-2024)
  • Table 187. Middle East Cardiac Marker, by Application USD Million (2019-2024)
  • Table 188. Middle East Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 189. Africa Cardiac Marker, by Type USD Million (2019-2024)
  • Table 190. Africa Cardiac Marker, by Application USD Million (2019-2024)
  • Table 191. Africa Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 192. North America Cardiac Marker, by Country USD Million (2019-2024)
  • Table 193. North America Cardiac Marker, by Type USD Million (2019-2024)
  • Table 194. North America Cardiac Marker, by Application USD Million (2019-2024)
  • Table 195. North America Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 196. United States Cardiac Marker, by Type USD Million (2019-2024)
  • Table 197. United States Cardiac Marker, by Application USD Million (2019-2024)
  • Table 198. United States Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 199. Canada Cardiac Marker, by Type USD Million (2019-2024)
  • Table 200. Canada Cardiac Marker, by Application USD Million (2019-2024)
  • Table 201. Canada Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 202. Mexico Cardiac Marker, by Type USD Million (2019-2024)
  • Table 203. Mexico Cardiac Marker, by Application USD Million (2019-2024)
  • Table 204. Mexico Cardiac Marker, by Testing USD Million (2019-2024)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cardiac Marker: by Type USD Million (2013-2018)
  • Figure 5. Global Cardiac Marker: by Application USD Million (2013-2018)
  • Figure 6. Global Cardiac Marker: by Testing USD Million (2013-2018)
  • Figure 7. South America Cardiac Marker Share (%), by Country
  • Figure 8. Asia Pacific Cardiac Marker Share (%), by Country
  • Figure 9. Europe Cardiac Marker Share (%), by Country
  • Figure 10. MEA Cardiac Marker Share (%), by Country
  • Figure 11. North America Cardiac Marker Share (%), by Country
  • Figure 12. Global Cardiac Marker share by Players 2018 (%)
  • Figure 13. Global Cardiac Marker share by Players (Top 3) 2018(%)
  • Figure 14. Global Cardiac Marker share by Players (Top 5) 2018(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Roche Diagnostics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. Roche Diagnostics (Switzerland) Revenue: by Geography 2018
  • Figure 18. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 19. Abbott Laboratories (United States) Revenue: by Geography 2018
  • Figure 20. Siemens AG (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Siemens AG (Germany) Revenue: by Geography 2018
  • Figure 22. BG Medicine (Cambodia) Revenue, Net Income and Gross profit
  • Figure 23. BG Medicine (Cambodia) Revenue: by Geography 2018
  • Figure 24. Biomerieux (France) Revenue, Net Income and Gross profit
  • Figure 25. Biomerieux (France) Revenue: by Geography 2018
  • Figure 26. Critical Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 27. Critical Diagnostics (United States) Revenue: by Geography 2018
  • Figure 28. LSI Medience Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 29. LSI Medience Corporation (Japan) Revenue: by Geography 2018
  • Figure 30. DiaDexus (United States) Revenue, Net Income and Gross profit
  • Figure 31. DiaDexus (United States) Revenue: by Geography 2018
  • Figure 32. Danaher Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 33. Danaher Corporation (United States) Revenue: by Geography 2018
  • Figure 34. Response Biomedical Corporation (Canada) Revenue, Net Income and Gross profit
  • Figure 35. Response Biomedical Corporation (Canada) Revenue: by Geography 2018
  • Figure 36. Global Cardiac Marker: by Type USD Million (2019-2024)
  • Figure 37. Global Cardiac Marker: by Application USD Million (2019-2024)
  • Figure 38. Global Cardiac Marker: by Testing USD Million (2019-2024)
  • Figure 39. South America Cardiac Marker Share (%), by Country
  • Figure 40. Asia Pacific Cardiac Marker Share (%), by Country
  • Figure 41. Europe Cardiac Marker Share (%), by Country
  • Figure 42. MEA Cardiac Marker Share (%), by Country
  • Figure 43. North America Cardiac Marker Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Roche Diagnostics (Switzerland)
  • Abbott Laboratories (United States)
  • Siemens AG (Germany)
  • BG Medicine (Cambodia)
  • Biomerieux (France)
  • Critical Diagnostics (United States)
  • LSI Medience Corporation (Japan)
  • diaDexus (United States)
  • Danaher Corporation (United States)
  • Response Biomedical Corporation (Canada)
Additional players considered in the study are as follows:
Singulex Inc. (United States) , Thermo Fisher Scientific (United States) , Trinity Biotech (Ireland) , Lee BioSolutions Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation